PRNewsWire
24 Jun 2026, 12:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Eli Lilly has successfully completed the acquisition of Centessa Pharmaceuticals. — Acquisition completions signal strategic expansion and the absorption of new intellectual property, though the impact is moderate as the target is clinical-stage.
+0.40Lilly acquires a clinical portfolio of orexin receptor 2 agonists for the treatment of narcolepsy and other sleep-wake disorders. — Adding a specialized pipeline in neuroscience diversifies Lilly's growth drivers beyond its current primary focus on obesity and diabetes.
+0.30Which stocks this story touches
The company successfully completed the acquisition of Centessa Pharmaceuticals to expand its neuroscience pipeline for sleep-wake disorders.
Continue reading
6 related stories
Top 2 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
